BACKGROUNDBarry N. Silberg, M.D., F.A.C.S., is the Executive Director of the Santa Rosa Antibiotic Effectiveness Project, Inc., and is the investigator-sponsor of the current study.
treatmentA promising new treatment for soft tissue infection, including Methicillin-resistant Staphylococcus Aureus (MRSA).
CURRENT STUDYAn FDA and WIRB approved expanded access study is currently in progress at Palm Drive Hospital, Sebastopol, California.
Promising new technology
The Santa Rosa Antibiotic Effectiveness Project is a 501(c)(3) nonprofit corporation that has been formed to advance the science of antibiotic medicine and to educate the public about our research in antibiotic effectiveness, which will benefit individuals and the community.
A study for direct antibiotic delivery, which offers a promising new way to treat soft tissue infections, including Methicillin-resistant Staphylococcus Aureus (MRSA), was approved on January 14, 2014, and is currently in progress at Palm Drive Hospital, 501 Petaluma Avenue, Sebastopol, California 95472. Treating physicians may contact the Palm Drive Hospital Wound Care Center at (707) 823-8511.
FDA and Western Institutional Review Board (WIRB) approves new Expanded Access Study - Intermediate Population at Palm Drive Hospital, 501 Petaluma Avenue, Sebastopol, California.